CHF59.00
1.67% yesterday
SIX Swiss Exchange, Jun 13, 05:31 pm CET
ISIN
NL0011832936
Symbol
COPN
Sector
Industry

COSMO Pharmaceuticals Stock price

CHF59.00
+5.90 11.11% 1M
-1.30 2.16% 6M
-4.70 7.38% YTD
-13.50 18.62% 1Y
-21.10 26.34% 5Y
-119.00 66.85% 10Y
+36.70 164.57% 20Y
SIX Swiss Exchange, Closing price Fri, Jun 13 2025
-1.00 1.67%
ISIN
NL0011832936
Symbol
COPN
Sector
Industry

Key metrics

Market capitalization CHF1.01b
Enterprise Value CHF878.27m
P/E (TTM) P/E ratio 7.85
EV/FCF (TTM) EV/FCF 5.98
EV/Sales (TTM) EV/Sales 3.51
P/S ratio (TTM) P/S ratio 4.04
P/B ratio (TTM) P/B ratio 2.02
Dividend yield 3.30%
Last dividend (FY25) CHF1.95
Revenue growth (TTM) Revenue growth 187.54%
Revenue (TTM) Revenue CHF250.16m
EBIT (operating result TTM) EBIT CHF139.60m
Free Cash Flow (TTM) Free Cash Flow CHF146.99m
Cash position CHF134.05m
EPS (TTM) EPS CHF7.52
P/E forward 300.61
P/S forward 10.35
EV/Sales forward 8.99
Show more

Is COSMO Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

COSMO Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast COSMO Pharmaceuticals:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast COSMO Pharmaceuticals:

Buy
100%

Financial data from COSMO Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
250 250
188% 188%
100%
- Direct Costs 43 43
15% 15%
17%
208 208
314% 314%
83%
- Selling and Administrative Expenses 34 34
21% 21%
14%
- Research and Development Expense 37 37
46% 46%
15%
151 151
7,272% 7,272%
60%
- Depreciation and Amortization 12 12
202% 202%
5%
EBIT (Operating Income) EBIT 140 140
8,040% 8,040%
56%
Net Profit 125 125
1,336% 1,336%
50%

In millions CHF.

Don't miss a Thing! We will send you all news about COSMO Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.

Head office Netherlands
CEO Giovanni Napoli
Employees 322
Founded 2016
Website www.cosmopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today